{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-012085","form_type":"8-K","ticker":"MIRA","cik":"0001904286","company_name":"MIRA PHARMACEUTICALS, INC.","filed_at":"2026-03-23T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.731712+00:00","generated_at":"2026-05-15T09:24:38.128841+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Mira-55 shows no cannabinoid-like CNS side effects in preclinical studies; advancing toward IND for inflammatory pain","bullets":["Mira-55 tested at 10, 30, and 100 mg/kg in CNS assays; no psychogenic, motor, or anxiogenic effects observed.","No catalepsy or sedation; dose-dependent increase in time spent in open arms of Elevated Plus Maze (anxiety reduction).","Rimonabant (positive control) showed anxiety-like behavior, validating assay sensitivity.","Prior data demonstrated Mira-55 produced morphine-comparable analgesia in inflammatory pain model without opioid risks.","Company plans IND submission for inflammatory pain; additional preclinical studies ongoing."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-012085","json":"https://secwatch.observer/filing/0001493152-26-012085.json","markdown":"https://secwatch.observer/filing/0001493152-26-012085.md","text":"https://secwatch.observer/filing/0001493152-26-012085.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1904286/000149315226012085/0001493152-26-012085-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1904286/000149315226012085/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T09:24:38.128841+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}